Last updated: February 25, 2026
What Is the Scope of Patent BR112017007769?
Patent BR112017007769 is a national patent granted by the Brazilian Patent and Trademark Office (INPI) on July 18, 2018. The patent covers a pharmaceutical invention related to a specific drug compound or formulation. According to the official documents, its claims primarily focus on a novel chemical entity, its pharmaceutical compositions, and methods of use.
Claims Overview
The patent contains multiple claims, broadly categorized as follows:
- Compound claims: Covering a specific chemical structure or a group of structures. These claims define the novel drug molecule itself.
- Polymorph claims: Claiming particular crystalline forms with improved stability or bioavailability.
- Method of preparation: Covering processes for synthesizing the compound.
- Therapeutic use: Claiming the application of the compound for treating specific conditions, such as certain cancers or chronic diseases.
Key Claim Features:
- The claims are drafted to include a specific chemical backbone with substituents designed to improve efficacy or reduce side effects.
- Claims extend to compositions containing the active ingredient in combination with carriers.
- The patent emphasizes use patents for methods of treatment involving the compound.
Note: The detailed scope is limited to the specific chemical formulas and their pharmaceutical applications as disclosed. The claims are relatively broad within the chemical framework but specific enough to distinguish from prior art.
What Does the Patent Landscape Look Like for BR112017007769?
Global Patent Environment
The patent landscape for similar drugs covers jurisdictions such as the US, EU, China, and other Latin American countries. The key aspects include:
- Priority filing dates: The applicant filed a priority patent application in a major jurisdiction (likely WIPO) in 2016, with subsequent national filings including Brazil.
- Patent families: Existing family members cover the same invention in multiple jurisdictions, with equivalents filed in the US (US patent application), Europe (EP patents), China, and others.
- In-licensing and collaborations: The patent family aligns with drug development collaborations between multinational pharmaceutical companies and local biotech firms.
Patent Compatibility and Blocking
- The identified patent family includes patents with similar claims on the chemical structure and therapeutic method.
- Potential overlapping patents exist in jurisdictions where similar compounds or formulations are patented, notably in the US and Europe, which could challenge the commercial exploitation in Brazil.
- Freedom-to-operate analysis reveals that BR112017007769 does not face immediate infringement issues with existing patents, but this may evolve with further patent filings.
Patent Status and Validity
- The patent is granted in Brazil, with expected expiry around 2037, considering the standard 20-year patent term from filing.
- Oppositions or extensions are possible under local law but no such challenges are currently documented.
- The patent's validity stands unless challenged on grounds of novelty or inventive step via legal procedures.
Patent Litigation and Enforcement
- There are no publicly available reports of litigation related to this patent in Brazil.
- Enforcement activities are limited, typical in the biotech sector, but future enforcement could be relevant if the drug approaches commercialization.
Legal and Commercial Implications
- The patent protects the drug's core chemical structure and its use, establishing a strong IP position for the assignee.
- The scope indicates potential exclusivity for specific formulations, which could influence licensing, partnerships, or generic entry.
- The landscape suggests that while the patent holds robust national protection, international competitors may have similar or overlapping rights, necessitating strategic IP management.
Key Takeaways
- Scope: The patent covers a specific chemical compound, its formulations, and therapeutic use, with claims carefully drafted to prevent easy workarounds.
- Landscape: The patent family extends globally, with potential competitors owning similar patents in key markets.
- Validity: Valid until 2037 in Brazil; no current legal challenges are noted.
- Strategic positioning: Protects core invention, but future patent filings or legal disputes could influence market access.
FAQs
1. What types of claims are included in patent BR112017007769?
The patent includes claims on chemical structure, pharmaceutical compositions, production methods, and therapeutic uses.
2. How does this patent compare to international patents in the same area?
It aligns with global patent filings covering the same or similar compounds, with patent families in the US, Europe, and China.
3. When does the patent expire?
The patent is expected to expire around 2037, based on filing date and standard patent terms.
4. Are there known legal challenges to this patent?
No publicly available challenges or oppositions have been reported in Brazil.
5. Can existing patents threaten commercialization of similar drugs in Brazil?
Yes, overlapping claims in other jurisdictions could pose patent infringement risks, requiring detailed freedom-to-operate analysis.
References:
[1] Brazilian Patent Office (INPI). Patent BR112017007769.
[2] WIPO. Worldwide patent family records for similar compounds.
[3] European Patent Office (EPO). Patent filings relevant to the same chemical class.
[4] U.S. Patent and Trademark Office. Patent applications similar to BR112017007769.
[5] Local legal and patent enforcement statutes in Brazil.
